Free Trial

ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis

+0.02 (+0.47%)
(As of 05/24/2024 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
85,800 shs
Average Volume
284,011 shs
Market Capitalization
$3.58 million
P/E Ratio
Dividend Yield
Price Target

ZyVersa Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
2,684.2% Upside
$120.00 Price Target
Short Interest
2.08% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($15.05) to ($25.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.52 out of 5 stars

ZVSA stock logo

About ZyVersa Therapeutics Stock (NASDAQ:ZVSA)

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

ZVSA Stock Price History

ZVSA Stock News Headlines

What's Going On With ZyVersa Stock?
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?
See More Headlines
Receive ZVSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$13.44 per share


Free Float
Market Cap
$3.58 million
Not Optionable
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Stephen C. Glover (Age 64)
    Co-Founder, Chairman, CEO & President
    Comp: $775k
  • Mr. Peter Wolfe (Age 56)
    CFO & Secretary
    Comp: $477.5k
  • Ms. Karen A. Cashmere (Age 72)
    Chief Commercial Officer
    Comp: $410k
  • Ms. Melda Uzbil O'connell
    Senior Vice President of Corporate Development
  • Dr. Pablo A. Guzman FACC (Age 74)
    M.D., Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board

ZVSA Stock Analysis - Frequently Asked Questions

Should I buy or sell ZyVersa Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ZyVersa Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZVSA shares.
View ZVSA analyst ratings
or view top-rated stocks.

What is ZyVersa Therapeutics' stock price target for 2024?

1 equities research analysts have issued twelve-month price targets for ZyVersa Therapeutics' shares. Their ZVSA share price targets range from $120.00 to $120.00. On average, they predict the company's share price to reach $120.00 in the next year. This suggests a possible upside of 2,684.2% from the stock's current price.
View analysts price targets for ZVSA
or view top-rated stocks among Wall Street analysts.

How have ZVSA shares performed in 2024?

ZyVersa Therapeutics' stock was trading at $9.00 at the beginning of 2024. Since then, ZVSA stock has decreased by 52.1% and is now trading at $4.31.
View the best growth stocks for 2024 here

When is ZyVersa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 19th 2024.
View our ZVSA earnings forecast

When did ZyVersa Therapeutics' stock split?

Shares of ZyVersa Therapeutics reverse split on Friday, April 26th 2024. The 1-10 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of ZyVersa Therapeutics?

Shares of ZVSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ZVSA) was last updated on 5/27/2024 by Staff

From Our Partners